The Food and Drug Administration (FDA) has approved a 10mg/mL solution for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 mutations. This solution is of ramucirumab injection combined with erlotinib. This combination is now the first and only FDA-approved anti-VEGFR/EGFR TKI combination therapy. This